North Carolina is currently home to 2735 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Winston-Salem, Charlotte and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Recruiting
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2022
Locations: Levine Cancer Institute - Atrium Health, Charlotte, North Carolina
Conditions: Locally Advanced Pancreatic Cancer
Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19
Recruiting
This is a multi-center, randomized, triple-blind, placebo-controlled (RCT) study to evaluate the efficacy and safety of Dapsone in older adults, and/or in adult patients (≥40yrs of age) with at least one high-risk comorbidity, among those with confirmed SARS-CoV-2 infection. 3000 infected patients diagnosed with COVID-19, non-hospitalized at the time of enrollment, meeting all inclusion and no exclusion criteria will be randomized (1:1 allocation ratio) to receive either Dapsone or placebo tabl... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
02/22/2022
Locations: Peters Medical Research, LLC, High Point, North Carolina
Conditions: COVID-19
Ultrasound Imaging Based Sensing of Human Ankle Motion Intent and Control Strategies for Ankle Assistance
Recruiting
Robotic therapies aim to improve limb function in individuals with neurological injury. Modulation of robotic assistance in many of these therapies is achieved by measuring the extant volitional strength of limb muscles. However, current sensing techniques, such as electromyography, are often unable to correctly measure the voluntary strength of a targeted muscle. The difficulty is due to their inability to remove ambiguity caused by interference from activities of neighboring muscles. These dis... Read More
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
02/16/2022
Locations: 1807 N. Fordham Blvd. UNC Center for Rehabilitation Care of Chapel Hill, Chapel Hill, North Carolina
Conditions: Incomplete Spinal Cord Injury, Transverse Myelitis
Development of a Game-supported Intervention
Recruiting
The investigators will develop and pilot test an innovative computer-assisted behavior intervention (CABI) for middle school students with attention-deficit/hyperactivity disorder (ADHD). The CABI will deliver evidence-based behavior interventions for ADHD in a manner that is acceptable to teachers and motivating for students. The key element of the CABI is a serious game that will teach and encourage rehearsal of ADHD coping skills in an engaging game environment. Transfer of those skills to au... Read More
Gender:
All
Ages:
Between 11 years and 14 years
Trial Updated:
02/16/2022
Locations: East Carolina University, Greenville, North Carolina
Conditions: Attention Deficit Hyperactivity Disorder
Treatment of Radiation and Cisplatin Induced Toxicities With Tempol
Recruiting
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2022
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Mucositis, Nephrotoxicity, Ototoxicity
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
Recruiting
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2022
Locations: Coronavirus Research Institute-Testing Site, Durham, North Carolina
Conditions: Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Recruiting
A Phase 1, first-in-human, open-label, multicenter, dose escalation and dose expansion study to investigate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of ZX-4081 administered orally (PO) twice daily (BID) in 28-day cycles in patients with Advanced Solid Tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2022
Locations: Carolina BioOncology, Huntersville, North Carolina
Conditions: Advanced Solid Tumor
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Charlotte, North Carolina
Conditions: Chronic Lymphocytic Leukemia
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Duke Cancer Center, Duke University Medical Center, Durham, North Carolina
Conditions: Solid Tumors, GI Cancer
A Phase 3, Multi-Center Study Evaluating PL9643 in Patients With Dry Eye
Recruiting
This is a multi-center, double-masked, randomized, vehicle-controlled study testing PL9643, an opthalmic solution to determine if safe and efficacious for dry eye patients. After a 2-week run-in period, patients will be randomized equally to the PL9643 opthalmic solution or vehicle opthalmic solution administered bilaterally three times a day for 12 weeks. A Data Monitoring Committee will be engaged to review interim data.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/08/2022
Locations: Palatin Clinical Site #8, Mint Hill, North Carolina
Conditions: Dry Eye, Dry Eye Syndromes
Longitudinal Performance of Epi proColon
Recruiting
This study will evaluate longitudinal performance of Epi proColon with respect to test positivity, longitudinal adherence to Epi proColon screening, adherence to follow-up colonoscopy and diagnostic yield, as well as assay failure rates.
Gender:
All
Ages:
Between 50 years and 74 years
Trial Updated:
10/29/2021
Locations: Duke University, Durham, North Carolina
Conditions: Colorectal Cancer, Colorectal Neoplasms
Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects
Recruiting
The APR began as the 'Zidovudine in pregnancy Registry' in January 1989 and became the 'Antiretroviral Pregnancy Registry' in January, 1993. The purpose of the APR is to detect any major teratogenic effects involving any of the Registry drugs when administered to pregnant HIV positive women. The Registry is intended to provide an early signal of teratogenicity associated with prenatal use of the antiretroviral drugs. The Registry collects data on prenatal exposures to antiretroviral drugs, poten... Read More
Gender:
Female
Ages:
All
Trial Updated:
10/04/2021
Locations: GSK Investigational Site, Wilmington, North Carolina
Conditions: Infection, Human Immunodeficiency Virus, HIV Infections